Cold Atmospheric Plasma in Oncology: A Review and Perspectives on Its Application in Veterinary Oncology

Cold atmospheric plasma (CAP) is emerging as an innovative approach for cancer treatment because of its selectivity for malignant cells and absence of significant adverse effects. While modern oncological therapies face challenges such as tumor heterogeneity and treatment resistance, CAP presents itself as a low-cost and environmentally sustainable alternative. Its mechanisms of action involve reactive oxygen and nitrogen species (RONS), UV radiation, and electromagnetic fields, which induce cell death. Preclinical and clinical studies have demonstrated the efficacy of CAP, with devices such as dielectric barrier discharge (DBD) and the plasma jet developed to minimize damage to healthy cells. Some CAP devices are already approved for clinical use, showing safety and efficacy. However, the standardization of treatments remains a challenge due to the variety of devices and parameters used. Although CAP has shown promising cytotoxic effects in vitro and in animal models, especially in different cancer cell lines, further research, particularly in vivo and in veterinary medicine, is needed to optimize its clinical use and maximize its efficacy in combating cancer.